Incidence of bleeding events in patients on concomitant tyrosine kinase inhibitors and selective serotonin reuptake inhibitors.

Vinayak Venkataraman,John R Bales,Jessie Signorelli,Gabriela S Hobbs

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners（2022）

引用 0|浏览0

暂无评分

摘要

Concomitant use of TKIs and SSRIs does not appear to increase the total risk of bleeding or thrombotic events compared to patients on TKIs only. However, concomitant use of TKIs and SSRIs may increase risk of intracranial bleeding. Further work is needed to fully assess this risk.

查看译文

关键词

Tyrosine kinase inhibitors,bleeding,chronic myeloid leukemia,selective serotonin reuptake inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要